首页> 外文期刊>Urology >Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review.
【24h】

Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review.

机译:口服曲唑酮作为勃起功能障碍的经验疗法:回顾性回顾。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES. Anecdotal reports of increased libido and sexual function in patients taking trazodone have led to its empirical use in patients with erectile dysfunction. A retrospective review of patient-reported responses to trazodone was performed to outline the efficacy and side-effect profile of this agent. METHODS. Between 1989 and 1994, 182 patients were placed on oral trazodone as empirical therapy for erectile dysfunction. Patients ranged in age from 26 to 85 years, with a mean of 60 years. Patients were evaluated before receiving trazodone with a thorough medical history and physical examination. Known risk factors for erectile dysfunction were assigned based on historical information and the findings of the examination. Patients received trazodone for at least 2 consecutive months, with daily doses starting at 25 mg. RESULTS. One hundred twenty-seven patients were available for follow-up by a standardized questionnaire regarding perceived improvement in erectile function, sexual function, and side effects. In patients less than 60 years of age, with no known risk factors for erectile dysfunction, 21 of 27 (78%) showed significant improvement in erectile ability. Smokers and patients older than 60 years with a history of significant peripheral vascular disease responded poorly to trazodone therapy. The duration of erectile dysfunction was inversely related to a response to trazodone. Of patients with a duration of impotence less than 12 months, 48% reported a positive response. Only 16% of patients with duration of erectile dysfunction greater than 60 months reported improvement in erections and sexual function. Trazodone was well tolerated by this population, with 62% reporting no side effects. CONCLUSIONS. Despite the limitations of a nonrandomized, retrospective study, trazodone appears to benefit younger patients with erectile dysfunction with few known risk factors. A prospective, placebo-controlled trial is needed to confirm the observations of this pilot study.
机译:目标传闻服用曲唑酮的患者性欲和性功能增加的报道已导致其在勃起功能障碍患者中的​​经验性使用。对患者报告的曲唑酮反应进行了回顾性研究,以概述该药物的疗效和副作用。方法。在1989年至1994年之间,有182例患者接受口服曲唑酮作为勃起功能障碍的经验疗法。患者的年龄为26至85岁,平均60岁。在接受曲唑酮治疗之前对患者进行了全面的病史和身体检查。根据历史资料和检查结果确定已知的勃起功能障碍危险因素。患者至少连续2个月接受曲唑酮治疗,每日剂量从25 mg开始。结果。一百二十七名患者可以通过标准化问卷进行随访,这些问卷涉及勃起功能,性功能和副作用的改善。在不到60岁的患者中,没有已知的勃起功能障碍危险因素,在27名患者中有21名(78%)表现出勃起能力的显着改善。吸烟者和年龄超过60岁且有重大外周血管疾病史的患者对曲唑酮治疗的反应较差。勃起功能障碍的持续时间与对曲唑酮的反应成反比。阳imp持续时间少于12个月的患者中,有48%报告阳性反应。勃起功能障碍持续时间超过60个月的患者中,只有16%的勃起和性功能得到改善。该人群对曲唑酮的耐受性良好,有62%的人无副作用。结论。尽管非随机回顾性研究存在局限性,曲唑酮似乎可以使年轻的勃起功能障碍患者受益,而已知危险因素很少。需要一项前瞻性,安慰剂对照的试验来确认该初步研究的观察结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号